通过基于集成视觉转换器的模型监测乳腺癌患者对新辅助化疗的病理完全反应。

IF 2.9 2区 医学 Q2 ONCOLOGY
Cancer Medicine Pub Date : 2024-12-18 DOI:10.1002/cam4.70482
Maria Colomba Comes, Annarita Fanizzi, Samantha Bove, Luca Boldrini, Agnese Latorre, Deniz Can Guven, Serena Iacovelli, Tiziana Talienti, Alessandro Rizzo, Francesco Alfredo Zito, Raffaella Massafra
{"title":"通过基于集成视觉转换器的模型监测乳腺癌患者对新辅助化疗的病理完全反应。","authors":"Maria Colomba Comes,&nbsp;Annarita Fanizzi,&nbsp;Samantha Bove,&nbsp;Luca Boldrini,&nbsp;Agnese Latorre,&nbsp;Deniz Can Guven,&nbsp;Serena Iacovelli,&nbsp;Tiziana Talienti,&nbsp;Alessandro Rizzo,&nbsp;Francesco Alfredo Zito,&nbsp;Raffaella Massafra","doi":"10.1002/cam4.70482","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Morphological and vascular characteristics of breast cancer can change during neoadjuvant chemotherapy (NAC). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-acquired pre- and mid-treatment quantitatively capture information about tumor heterogeneity as potential earlier indicators of pathological complete response (pCR) to NAC in breast cancer.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>This study aimed to develop an ensemble deep learning-based model, exploiting a Vision Transformer (ViT) architecture, which merges features automatically extracted from five segmented slices of both pre- and mid-treatment exams containing the maximum tumor area, to predict and monitor pCR to NAC.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Imaging data analyzed in this study referred to a cohort of 86 breast cancer patients, randomly split into training and test sets at a ratio of 8:2, who underwent NAC and for which information regarding the pCR status was available (37.2% of patients achieved pCR). We further validated our model using a subset of 20 patients selected from the publicly available I-SPY2 trial dataset (independent test).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The performances of the proposed model were assessed using standard evaluation metrics, and promising results were achieved: area under the curve (AUC) value of 91.4%, accuracy value of 82.4%, a specificity value of 80.0%, a sensitivity value of 85.7%, precision value of 75.0%, F-score value of 80.0%, and G-mean value of 82.8%. The results obtained from the independent test show an AUC of 81.3%, an accuracy of 80.0%, a specificity value of 76.9%, a sensitivity of 85.0%, a precision of 66.7%, an F-score of 75.0%, and a G-mean of 81.2%.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>As far as we know, our research is the first proposal using ViTs on DCE-MRI exams to monitor pCR over time during NAC.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Finally, the changes in DCE-MRI at pre- and mid-treatment could affect the accuracy of pCR prediction to NAC.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 24","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70482","citationCount":"0","resultStr":"{\"title\":\"Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model\",\"authors\":\"Maria Colomba Comes,&nbsp;Annarita Fanizzi,&nbsp;Samantha Bove,&nbsp;Luca Boldrini,&nbsp;Agnese Latorre,&nbsp;Deniz Can Guven,&nbsp;Serena Iacovelli,&nbsp;Tiziana Talienti,&nbsp;Alessandro Rizzo,&nbsp;Francesco Alfredo Zito,&nbsp;Raffaella Massafra\",\"doi\":\"10.1002/cam4.70482\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Morphological and vascular characteristics of breast cancer can change during neoadjuvant chemotherapy (NAC). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-acquired pre- and mid-treatment quantitatively capture information about tumor heterogeneity as potential earlier indicators of pathological complete response (pCR) to NAC in breast cancer.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>This study aimed to develop an ensemble deep learning-based model, exploiting a Vision Transformer (ViT) architecture, which merges features automatically extracted from five segmented slices of both pre- and mid-treatment exams containing the maximum tumor area, to predict and monitor pCR to NAC.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>Imaging data analyzed in this study referred to a cohort of 86 breast cancer patients, randomly split into training and test sets at a ratio of 8:2, who underwent NAC and for which information regarding the pCR status was available (37.2% of patients achieved pCR). We further validated our model using a subset of 20 patients selected from the publicly available I-SPY2 trial dataset (independent test).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The performances of the proposed model were assessed using standard evaluation metrics, and promising results were achieved: area under the curve (AUC) value of 91.4%, accuracy value of 82.4%, a specificity value of 80.0%, a sensitivity value of 85.7%, precision value of 75.0%, F-score value of 80.0%, and G-mean value of 82.8%. The results obtained from the independent test show an AUC of 81.3%, an accuracy of 80.0%, a specificity value of 76.9%, a sensitivity of 85.0%, a precision of 66.7%, an F-score of 75.0%, and a G-mean of 81.2%.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Discussion</h3>\\n \\n <p>As far as we know, our research is the first proposal using ViTs on DCE-MRI exams to monitor pCR over time during NAC.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Finally, the changes in DCE-MRI at pre- and mid-treatment could affect the accuracy of pCR prediction to NAC.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"13 24\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-12-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70482\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70482\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70482","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:乳腺癌的形态和血管特征在新辅助化疗(NAC)期间会发生改变。动态对比增强磁共振成像(DCE-MRI)获得的治疗前和治疗中期定量捕获肿瘤异质性信息,作为乳腺癌NAC病理完全反应(pCR)的潜在早期指标。目的:本研究旨在开发一种基于集成深度学习的模型,利用视觉转换器(Vision Transformer, ViT)架构,将从治疗前和中期检查中包含最大肿瘤面积的五个分段切片中自动提取的特征合并在一起,以预测和监测pCR到NAC。材料和方法:本研究分析的影像学数据为86例乳腺癌患者,随机分为训练组和测试组,比例为8:2,接受NAC治疗,并获得pCR状态信息(37.2%的患者获得pCR)。我们使用从公开可用的I-SPY2试验数据集(独立测试)中选择的20例患者的子集进一步验证了我们的模型。结果:采用标准评价指标对模型的性能进行了评价,取得了良好的结果:曲线下面积(AUC)值为91.4%,准确度值为82.4%,特异性值为80.0%,灵敏度值为85.7%,精度值为75.0%,f评分值为80.0%,g均值为82.8%。独立检测结果显示,AUC为81.3%,准确度为80.0%,特异性值为76.9%,敏感性为85.0%,精确度为66.7%,f评分为75.0%,g均值为81.2%。讨论:据我们所知,我们的研究是第一个在DCE-MRI检查中使用ViTs来监测NAC期间随时间变化的pCR的建议。结论:最后,DCE-MRI在治疗前和治疗中期的变化会影响pCR预测NAC的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model

Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model

Background

Morphological and vascular characteristics of breast cancer can change during neoadjuvant chemotherapy (NAC). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-acquired pre- and mid-treatment quantitatively capture information about tumor heterogeneity as potential earlier indicators of pathological complete response (pCR) to NAC in breast cancer.

Aims

This study aimed to develop an ensemble deep learning-based model, exploiting a Vision Transformer (ViT) architecture, which merges features automatically extracted from five segmented slices of both pre- and mid-treatment exams containing the maximum tumor area, to predict and monitor pCR to NAC.

Materials and Methods

Imaging data analyzed in this study referred to a cohort of 86 breast cancer patients, randomly split into training and test sets at a ratio of 8:2, who underwent NAC and for which information regarding the pCR status was available (37.2% of patients achieved pCR). We further validated our model using a subset of 20 patients selected from the publicly available I-SPY2 trial dataset (independent test).

Results

The performances of the proposed model were assessed using standard evaluation metrics, and promising results were achieved: area under the curve (AUC) value of 91.4%, accuracy value of 82.4%, a specificity value of 80.0%, a sensitivity value of 85.7%, precision value of 75.0%, F-score value of 80.0%, and G-mean value of 82.8%. The results obtained from the independent test show an AUC of 81.3%, an accuracy of 80.0%, a specificity value of 76.9%, a sensitivity of 85.0%, a precision of 66.7%, an F-score of 75.0%, and a G-mean of 81.2%.

Discussion

As far as we know, our research is the first proposal using ViTs on DCE-MRI exams to monitor pCR over time during NAC.

Conclusion

Finally, the changes in DCE-MRI at pre- and mid-treatment could affect the accuracy of pCR prediction to NAC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Medicine
Cancer Medicine ONCOLOGY-
CiteScore
5.50
自引率
2.50%
发文量
907
审稿时长
19 weeks
期刊介绍: Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信